-
Using Alzheimer's disease blood tests to accelerate clinical trial enrollment Alzheimers Dement. (IF 16.655) Pub Date : 2022-08-07 Suzanne E. Schindler, Yan Li, Melody Li, Alyssa Despotis, Ethan Park, Liberty Vittert, Barton H. Hamilton, Kyle B. Womack, Benjamin Saef, David M. Holtzman, John C. Morris, Randall J. Bateman, Mahendra R. Gupta
Screening potential participants in Alzheimer's disease (AD) clinical trials with amyloid positron emission tomography (PET) is often time consuming and expensive.
-
Testing the link between isoaspartate and Alzheimer's disease etiology Alzheimers Dement. (IF 16.655) Pub Date : 2022-08-04 Jijing Wang, Cong Guo, Zhaowei Meng, Marissa D. Zwan, Xin Chen, Sven Seelow, Susanna L. Lundström, Sergey Rodin, Charlotte E. Teunissen, Roman A. Zubarev
-
Cumulative loneliness and subsequent memory function and rate of decline among adults aged ≥50 in the United States, 1996 to 2016 Alzheimers Dement. (IF 16.655) Pub Date : 2022-08-03 Xuexin Yu, Ashly C. Westrick, Lindsay C. Kobayashi
The study objective was to investigate the association between loneliness duration and memory function over a 20-year period.
-
Cognitive resilience depends on white matter connectivity: The Maastricht Study Alzheimers Dement. (IF 16.655) Pub Date : 2022-08-03 Nathan R. DeJong, Jacobus F.A. Jansen, Martin P.J. van Boxtel, Miranda T. Schram, Coen D.A. Stehouwer, Pieter C. Dagnelie, Carla J.H. van der Kallen, Abraham A. Kroon, Anke Wesselius, Annemarie Koster, Walter H. Backes, Sebastian Köhler
Differences in brain network connectivity may reflect the capability of the neurological substrate to compensate for brain damage and preserve cognitive function (cognitive reserve). We examined the associations between white matter connectivity, brain damage markers, and cognition in a population sample of middle-aged individuals.
-
Phosphorylated tau sites that are elevated in Alzheimer's disease fluid biomarkers are visualized in early neurofibrillary tangle maturity levels in the post mortem brain Alzheimers Dement. (IF 16.655) Pub Date : 2022-08-03 Christina M. Moloney, Sydney A. Labuzan, Julia E. Crook, Habeeba Siddiqui, Monica Castanedes-Casey, Christian Lachner, Ronald C. Petersen, Ranjan Duara, Neill R. Graff-Radford, Dennis W. Dickson, Michelle M. Mielke, Melissa E. Murray
Alzheimer's disease (AD) biomarkers are increasingly more reliable in predicting neuropathology. To facilitate interpretation of phosphorylated tau sites as an early fluid biomarker, we sought to characterize which neurofibrillary tangle maturity levels (pretangle, intermediary 1, mature tangle, intermediary 2, and ghost tangle) are recognized.
-
Putting participants and study partners FIRST when clinical trials end early Alzheimers Dement. (IF 16.655) Pub Date : 2022-08-02 Emily A. Largent, Sarah Walter, Nancy Childs, Penny A. Dacks, Shana Dodge, Hana Florian, Jonathan Jackson, Jorge J. Llibre Guerra, Erin Iturriaga, David S. Miller, Monica Moreno, Rachel L. Nosheny, Thomas O. Obisesan, Elena Portacolone, Bernadette Siddiqi, Nina Silverberg, Rueben C. Warren, Kathleen A. Welsh-Bohmer, Rebecca M. Edelmayer
Between 2018 and 2019, multiple clinical trials ended earlier than planned, resulting in calls to improve communication with and support for participants and their study partners (“dyads”). The multidisciplinary Participant Follow-Up Improvement in Research Studies and Trials (Participant FIRST) Work Group met throughout 2021. Its goals were to identify best practices for communicating with and supporting
-
The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease Alzheimers Dement. (IF 16.655) Pub Date : 2022-07-31 Oskar Hansson, Rebecca M. Edelmayer, Adam L. Boxer, Maria C. Carrillo, Michelle M. Mielke, Gil D. Rabinovici, Stephen Salloway, Reisa Sperling, Henrik Zetterberg, Charlotte E. Teunissen
Blood-based markers (BBMs) have recently shown promise to revolutionize the diagnostic and prognostic work-up of Alzheimer's disease (AD), as well as to improve the design of interventional trials. Here we discuss in detail further research needed to be performed before widespread use of BBMs. We already now recommend use of BBMs as (pre-)screeners to identify individuals likely to have AD pathological
-
Rapid olfactory decline during aging predicts dementia and GMV loss in AD brain regions Alzheimers Dement. (IF 16.655) Pub Date : 2022-07-28 Rachel R. Pacyna, S. Duke Han, Kristen E. Wroblewski, Martha K. McClintock, Jayant M. Pinto
Longitudinal multivariable analyses are needed to determine if the rate of olfactory decline during normal cognition predicts subsequent Alzheimer's disease (AD) diagnoses and brain dysmorphology.
-
Does the imbalance in the apolipoprotein E isoforms underlie the pathophysiological process of sporadic Alzheimer's disease? Alzheimers Dement. (IF 16.655) Pub Date : 2022-07-28 Madia Lozupone, Bruno Pietro Imbimbo, Claudia Balducci, Filomena Lo Vecchio, Paola Bisceglia, Raffaela Rita Latino, Maurizio Leone, Vittorio Dibello, Vincenzo Solfrizzi, Antonio Greco, Antonio Daniele, Mark Watling, Davide Seripa, Francesco Panza
Human apolipoprotein E (apoE) is a 299-amino acid secreted glycoprotein binding cholesterol and phospholipids, and with three common isoforms (APOE ε2, APOE ε3, and APOE ε4). The exact mechanism by which APOE gene variants increase/decrease Alzheimer's disease (AD) risk is not fully understood, but APOE isoforms differently affect brain homeostasis and neuroinflammation, blood–brain barrier (BBB) permeability
-
Cerebral small vessel disease burden and cognitive and functional outcomes after stroke: A multicenter prospective cohort study Alzheimers Dement. (IF 16.655) Pub Date : 2022-07-25 Marios K. Georgakis, Rong Fang, Marco Düring, Frank A. Wollenweber, Felix J. Bode, Sebastian Stösser, Christine Kindlein, Peter Hermann, Thomas G. Liman, Christian H. Nolte, Lucia Kerti, Benno Ikenberg, Kathleen Bernkopf, Holger Poppert, Wenzel Glanz, Valentina Perosa, Daniel Janowitz, Michael Wagner, Katja Neumann, Oliver Speck, Laura Dobisch, Emrah Düzel, Benno Gesierich, Anna Dewenter, Annika Spottke
It remains unknown whether the global small vessel disease (SVD) burden predicts post-stroke outcomes.
-
Neighborhood segregation and cognitive change: Multi-Ethnic Study of Atherosclerosis Alzheimers Dement. (IF 16.655) Pub Date : 2022-07-23 Lilah M. Besser, Oanh L. Meyer, Miranda R. Jones, Duyen Tran, Michaela Booker, Diana Mitsova, Rachel Peterson, James E. Galvin, James R. Bateman, Kathleen M. Hayden, Timothy M. Hughes
We investigated associations between neighborhood racial/ethnic segregation and cognitive change.
-
Blood-based bioenergetic profiling reveals differences in mitochondrial function associated with cognitive performance and Alzheimer's disease Alzheimers Dement. (IF 16.655) Pub Date : 2022-07-23 Gargi Mahapatra, Zhengrong Gao, James R. Bateman, Samuel Neal Lockhart, Jaclyn Bergstrom, Amber Renee DeWitt, Jemima Elizabeth Piloso, Philip Adam Kramer, Jenny L. Gonzalez-Armenta, Kimberly Allison Amick, Ramon Casanova, Suzanne Craft, Anthony J. A. Molina
Despite evidence for systemic mitochondrial dysfunction early in Alzheimer's disease (AD) pathogenesis, reliable approaches monitoring these key bioenergetic alterations are lacking. We used peripheral blood mononuclear cells (PBMCs) and platelets as reporters of mitochondrial function in the context of cognitive impairment and AD.
-
Vitamin D intake and cognitive decline in Blacks and Whites: The role of diet and supplements Alzheimers Dement. (IF 16.655) Pub Date : 2022-07-22 Klodian Dhana, Lisa L. Barnes, Puja Agarwal, Xiaoran Liu, Anisa Dhana, Pankaja Desai, Neelum Aggarwal, Denis A. Evans, Kumar B. Rajan
To determine the role of vitamin D intake on cognitive decline among Blacks and Whites.
-
Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort Alzheimers Dement. (IF 16.655) Pub Date : 2022-07-21 Pratishtha Chatterjee, Steve Pedrini, James D. Doecke, Rohith Thota, Victor L. Villemagne, Vincent Doré, Abhay K. Singh, Penghao Wang, Stephanie Rainey-Smith, Christopher Fowler, Kevin Taddei, Hamid R. Sohrabi, Mark P. Molloy, David Ames, Paul Maruff, Christopher C. Rowe, Colin L. Masters, Ralph N. Martins
Plasma amyloid beta (Aβ)1-42/Aβ1-40 ratio, phosphorylated-tau181 (p-tau181), glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) are putative blood biomarkers for Alzheimer's disease (AD). However, head-to-head cross-sectional and longitudinal comparisons of the aforementioned biomarkers across the AD continuum are lacking.
-
Exploring links between 2-oxoglutarate-dependent oxygenases and Alzheimer's disease Alzheimers Dement. (IF 16.655) Pub Date : 2022-07-19 Haotian Liu, Yong Xie, Xia Wang, Martine I. Abboud, Chao Ma, Wei Ge, Christopher J. Schofield
Hypoxia, that is, an inadequate oxygen supply, is linked to neurodegeneration and patients with cardiovascular disease are prone to Alzheimer's disease (AD). 2-Oxoglutarate and ferrous iron-dependent oxygenases (2OGDD) play a key role in the regulation of oxygen homeostasis by acting as hypoxia sensors. 2OGDD also have roles in collagen biosynthesis, lipid metabolism, nucleic acid repair, and the regulation
-
Amyloid-beta misfolding and GFAP predict risk of clinical Alzheimer's disease diagnosis within 17 years Alzheimers Dement. (IF 16.655) Pub Date : 2022-07-19 Léon Beyer, Hannah Stocker, Dan Rujescu, Bernd Holleczek, Julia Stockmann, Andreas Nabers, Hermann Brenner, Klaus Gerwert
Blood-based biomarkers for Alzheimer's disease (AD) are urgently needed. Here, four plasma biomarkers were measured at baseline in a community-based cohort followed over 17 years, and the association with clinical AD risk was determined.
-
Dementia prevention: The potential long-term cost-effectiveness of the FINGER prevention program Alzheimers Dement. (IF 16.655) Pub Date : 2022-07-16 Anders Wimo, Ron Handels, Riitta Antikainen, Maria Eriksdotter, Linus Jönsson, Martin Knapp, Jenni Kulmala, Tiina Laatikainen, Jenni Lehtisalo, Markku Peltonen, Anders Sköldunger, Hilkka Soininen, Alina Solomon, Timo Strandberg, Jaakko Tuomilehto, Tiia Ngandu, Miia Kivipelto
The aim of this study was to estimate the potential cost-effectiveness of the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) program.
-
Differences in the measurement of cognition for the assessment of dementia across geographic contexts: Recommendations for cross-national research Alzheimers Dement. (IF 16.655) Pub Date : 2022-07-16 Emma Nichols, Derek K. Ng, Shablina Hayat, Kenneth M. Langa, Jinkook Lee, Andrew Steptoe, Jennifer A. Deal, Alden L. Gross
Most cognitive assessments have been developed in high-income countries but are used in diverse contexts. Differences in culture and context may affect the performance of cognitive items.
-
The landscape of metabolic brain alterations in Alzheimer's disease Alzheimers Dement. (IF 16.655) Pub Date : 2022-07-13 Richa Batra, Matthias Arnold, Maria A. Wörheide, Mariet Allen, Xue Wang, Colette Blach, Allan I. Levey, Nicholas T. Seyfried, Nilüfer Ertekin-Taner, David A. Bennett, Gabi Kastenmüller, Rima F. Kaddurah-Daouk, Jan Krumsiek
Alzheimer's disease (AD) is accompanied by metabolic alterations both in the periphery and the central nervous system. However, so far, a global view of AD-associated metabolic changes in the brain has been missing.
-
The impacts of health insurance and resource on the burden of Alzheimer's disease and related dementias in the world population Alzheimers Dement. (IF 16.655) Pub Date : 2022-07-12 Jin-Tao Wang, Gang Xu, Ru-Jing Ren, Ying Wang, Ran Tang, Qiang Huang, Jian-Ping Li, Murad Al-Nusaif, Wei-Dong Le, Gang Wang
The increasing prevalence of Alzheimer's disease and related dementias (ADRD) presents both a burden and an opportunity for intervention. This study aims to estimate the impacts of health insurance and resources on the burden attributed to ADRD.
-
Comparative analytical performance of multiple plasma Aβ42 and Aβ40 assays and their ability to predict positron emission tomography amyloid positivity Alzheimers Dement. (IF 16.655) Pub Date : 2022-07-12 Stephen Zicha, Randall J. Bateman, Leslie M. Shaw, Henrik Zetterberg, Anthony W. Bannon, Wesley A. Horton, Mike Baratta, Hartmuth C. Kolb, Iwona Dobler, Yulia Mordashova, Ziad S. Saad, David L. Raunig, Emmanouil (Manos) Spanakis, Yan Li, Suzanne E. Schindler, Kyle Ferber, Carrie E. Rubel, Robert L. Martone, Christopher J. Weber, Rebecca M. Edelmayer, Emily A. Meyers, James G. Bollinger, Erin G. Rosenbaugh
This report details the approach taken to providing a dataset allowing for analyses on the performance of recently developed assays of amyloid beta (Aβ) peptides in plasma and the extent to which they improve the prediction of amyloid positivity.
-
Automated detection of mild cognitive impairment and dementia from voice recordings: A natural language processing approach Alzheimers Dement. (IF 16.655) Pub Date : 2022-07-07 Samad Amini, Boran Hao, Lifu Zhang, Mengting Song, Aman Gupta, Cody Karjadi, Vijaya B. Kolachalama, Rhoda Au, Ioannis Ch. Paschalidis
Automated computational assessment of neuropsychological tests would enable widespread, cost-effective screening for dementia.
-
Toward rational use of cognitive training in those with mild cognitive impairment Alzheimers Dement. (IF 16.655) Pub Date : 2022-07-06 Benjamin M. Hampstead, Anthony Y. Stringer, Alexandru D. Iordan, Robert Ploutz-Snyder, K. Sathian
The term cognitive training includes a range of techniques that hold potential for treating cognitive impairment caused by neurologic injury and disease. Our central premise is that these techniques differ in their mechanisms of action and therefore engage distinct brain regions (or neural networks). We support this premise using data from a single-blind randomized-controlled trial in which patients
-
Longitudinal changes in brain oxygen extraction fraction (OEF) in older adults: Relationship to markers of vascular and Alzheimer's pathology Alzheimers Dement. (IF 16.655) Pub Date : 2022-07-06 Zixuan Lin, Chantelle Lim, Dengrong Jiang, Anja Soldan, Corinne Pettigrew, Kumiko Oishi, Yuxin Zhu, Abhay Moghekar, Peiying Liu, Marilyn Albert, Hanzhang Lu
Oxygen extraction fraction (OEF) reflects the balance between oxygen delivery and consumption. We longitudinally measured OEF in older adults to examine the relationship with markers of Alzheimer's disease (AD) and vascular pathology.
-
Blood extracellular vesicles carrying synaptic function- and brain-related proteins as potential biomarkers for Alzheimer's disease Alzheimers Dement. (IF 16.655) Pub Date : 2022-07-02 Chen Tian, Tessandra Stewart, Zhen Hong, Zhen Guo, Patrick Aro, David Soltys, Catherine Pan, Elaine R Peskind, Cyrus P. Zabetian, Leslie M. Shaw, Douglas Galasko, Joseph F Quinn, Min Shi, Jing Zhang
Objective and accessible markers for Alzheimer's disease (AD) and other dementias are critically needed.
-
Elevated blood pressure is associated with advanced brain aging in mid-life: A 30-year follow-up of The CARDIA Study Alzheimers Dement. (IF 16.655) Pub Date : 2022-07-02 Christina S. Dintica, Mohamad Habes, Guray Erus, Eric Vittinghoff, Christos Davatzikos, Ilya M. Nasrallah, Lenore J. Launer, Stephen Sidney, Kristine Yaffe
High blood pressure (BP) is a risk factor for late-life brain health; however, the association of elevated BP with brain health in mid-life is unclear.
-
Join your colleagues at AAIC® 2022 Alzheimers Dement. (IF 16.655) Pub Date : 2022-07-02
If you haven't already registered, there's still time to join your colleagues at the Alzheimer's Association International Conference® (AAIC) 2022. At AAIC, the globe's leading basic scientists, clinical researchers, early career investigators, clinicians, and members of the care research community share discoveries about Alzheimer's disease (AD) and dementia prevention, treatment, diagnosis, and more
-
Genome-wide association and multi-omics studies identify MGMT as a novel risk gene for Alzheimer's disease among women Alzheimers Dement. (IF 16.655) Pub Date : 2022-06-30 Jaeyoon Chung, Anjali Das, Xinyu Sun, Débora R. Sobreira, Yuk Yee Leung, Catherine Igartua, Sahar Mozaffari, Yi-Fan Chou, Sam Thiagalingam, Jesse Mez, Xiaoling Zhang, Gyungah R. Jun, Thor D. Stein, Brian W. Kunkle, Eden R. Martin, Margaret A. Pericak-Vance, Richard Mayeux, Jonathan L. Haines, Gerard D. Schellenberg, Marcelo A. Nobrega, Kathryn L. Lunetta, Jayant M. Pinto, Li-San Wang, Carole Ober,
Variants in the tau gene (MAPT) region are associated with breast cancer in women and Alzheimer's disease (AD) among persons lacking apolipoprotein E ε4 (ε4–).
-
Traumatic brain injury and post-traumatic stress disorder are not associated with Alzheimer's disease pathology measured with biomarkers Alzheimers Dement. (IF 16.655) Pub Date : 2022-06-29 Michael W. Weiner, Danielle Harvey, Susan M Landau, Dallas P. Veitch, Thomas C. Neylan, Jordan H. Grafman, Paul S. Aisen, Ronald C. Petersen, Clifford R. Jack Jr, Duygu Tosun, Leslie M. Shaw, John Q. Trojanowski, Andrew J. Saykin, Jacqueline Hayes, Charles De Carli
Epidemiological studies report an association between traumatic brain injury (TBI) and post-traumatic stress disorder (PTSD) and clinically diagnosed Alzheimer's disease (AD). We examined the association between TBI/PTSD and biomarker-defined AD.
-
The Spanish-English bilingual experience and cognitive change in Hispanics/Latinos from the Hispanic Community Health Study/Study of Latinos-Investigation of Neurocognitive Aging Alzheimers Dement. (IF 16.655) Pub Date : 2022-06-29 Melissa Lamar, Wassim Tarraf, Benson Wu, Krista M. Perreira, Richard B. Lipton, Tasneem Khambaty, Jianwen Cai, Maria M. Llabre, Linda C. Gallo, Martha L. Daviglus, Hector M. González
Studies suggest bilingualism may delay behavioral manifestations of adverse cognitive aging including Alzheimer's dementia.
-
Toward harmonization of strategies for investigating lucidity in AD/ADRD: A preliminary research framework Alzheimers Dement. (IF 16.655) Pub Date : 2022-06-27 Andrea Gilmore-Bykovskyi, Joan M. Griffin, Kimberly D. Mueller, Sam Parnia, Ann Kolanowski
Episodes of lucidity (ELs) in Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD), have garnered increasing attention as an important area of research. Efforts to study lucidity suffer from a lack of clear definitional criteria, inconsistent conceptualization, and diverse approaches to operationalizing features of these events. To advance systematic investigation of ELs in AD/ADRD
-
Hypertension and Alzheimer's disease pathology at autopsy: A systematic review Alzheimers Dement. (IF 16.655) Pub Date : 2022-06-27 Herrer Abdulrahman, Jan Willem van Dalen, Melina den Brok, Caitlin S. Latimer, Eric B. Larson, Edo Richard
Hypertension is an important risk factor for Alzheimer's disease (AD) and all-cause dementia. The mechanisms underlying this association are unclear. Hypertension may be associated with AD neuropathological changes (ADNC), but reports are sparse and inconsistent. This systematic review included 15 autopsy studies (n = 5879) from observational cohorts. Studies were highly heterogeneous regarding populations
-
Alzheimer's disease genetic burden is associated with mid-life depression among persons with normal cognition Alzheimers Dement. (IF 16.655) Pub Date : 2022-06-21 Thomas S. Wingo, Ekaterina S. Gerasimov, Se Min Canon, James J. Lah, Allan I. Levey, Aliza P. Wingo
Despite an established link between depression and higher Alzheimer's disease (AD) risk, it is unclear whether the conditions share pathophysiology. Here, we investigated whether depression manifesting after age 50 is associated with a genetic predisposition to AD.
-
Global incidence of young-onset dementia: A systematic review and meta-analysis Alzheimers Dement. (IF 16.655) Pub Date : 2022-06-17 Stevie Hendriks, Kirsten Peetoom, Christian Bakker, Raymond Koopmans, Wiesje van der Flier, Janne Papma, Frans Verhey, , Marjolein de Vugt, Sebastian Köhler
Reliable data on the incidence rates for young-onset dementia (YOD) are lacking, but are necessary for research on disease etiology and to raise awareness among health care professionals.
-
Description of a European memory clinic cohort undergoing amyloid-PET: The AMYPAD Diagnostic and Patient Management Study Alzheimers Dement. (IF 16.655) Pub Date : 2022-06-17 Daniele Altomare, Lyduine Collij, Camilla Caprioglio, Philip Scheltens, Bart N.M. van Berckel, Isadora Lopes Alves, Johannes Berkhof, Yvonne de Gier, Valentina Garibotto, Christian Moro, Léa Poitrine, Julien Delrieu, Pierre Payoux, Laure Saint-Aubert, José Luis Molinuevo, Oriol Grau-Rivera, Juan-Domingo Gispert, Carolina Minguillón, Karine Fauria, Marta Felez Sanchez, Andreea Rădoi, Alexander Drzezga
AMYPAD Diagnostic and Patient Management Study (DPMS) aims to investigate the clinical utility and cost-effectiveness of amyloid-PET in Europe. Here we present participants’ baseline features and discuss the representativeness of the cohort.
-
Trajectories of cognitive decline and dementia development: A 12-year longitudinal study Alzheimers Dement. (IF 16.655) Pub Date : 2022-06-17 Nicola M. Payton, Anna Marseglia, Giulia Grande, Laura Fratiglioni, Miia Kivipelto, Lars Bäckman, Erika J. Laukka
Mapping the preclinical dementia phase is important for early detection and evaluation of interventions. We assessed the trajectories of cognitive decline in preclinical dementia over 12 years and investigated whether being a fast decliner across 6 years is associated with increased risk of dementia the following 6 years.
-
The Latin American Brain Health Institute, a regional initiative to reduce the scale and impact of dementia Alzheimers Dement. (IF 16.655) Pub Date : 2022-06-16 Claudia Duran-Aniotz, Jorge Sanhueza, Lea T. Grinberg, Andrea Slachevsky, Victor Valcour, Ian Robertson, Brian Lawlor, Bruce Miller, Agustín Ibáñez
Latin American and Caribbean countries face complex challenges to improve brain health and reduce the impact of dementia. Regional hubs devoted to research, capacity building, implementation science, and education are critically needed. The Latin American Brain Health Institute represent an important step to address many of these needs.
-
Cardiometabolic multimorbidity accelerates cognitive decline and dementia progression Alzheimers Dement. (IF 16.655) Pub Date : 2022-06-16 Abigail Dove, Anna Marseglia, Ying Shang, Giulia Grande, Davide Liborio Vetrano, Erika J Laukka, Laura Fratiglioni, Weili Xu
Cardiometabolic diseases (CMDs) have been individually associated with adverse cognitive outcomes, but their combined effect has not been investigated.
-
Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected non-Alzheimer's disease pathophysiology Alzheimers Dement. (IF 16.655) Pub Date : 2022-06-14 Aurore Delvenne, Johan Gobom, Betty Tijms, Isabelle Bos, Lianne M. Reus, Valerija Dobricic, Mara ten Kate, Frans Verhey, Inez Ramakers, Philip Scheltens, Charlotte E. Teunissen, Rik Vandenberghe, Jolien Schaeverbeke, Silvy Gabel, Julius Popp, Gwendoline Peyratout, Pablo Martinez-Lage, Mikel Tainta, Magda Tsolaki, Yvonne Freund-Levi, Simon Lovestone, Johannes Streffer, Frederik Barkhof, Lars Bertram
Suspected non-Alzheimer's disease pathophysiology (SNAP) is a biomarker concept that encompasses individuals with neuronal injury but without amyloidosis. We aim to investigate the pathophysiology of SNAP, defined as abnormal tau without amyloidosis, in individuals with mild cognitive impairment (MCI) by cerebrospinal fluid (CSF) proteomics.
-
Test-retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction models Alzheimers Dement. (IF 16.655) Pub Date : 2022-06-14 Nicholas C. Cullen, Shorena Janelidze, Niklas Mattsson-Carlgren, Sebastian Palmqvist, Tobias Bittner, Ivonne Suridjan, Alexander Jethwa, Gwendlyn Kollmorgen, Wagner S. Brum, Henrik Zetterberg, Kaj Blennow, Erik Stomrud, Oskar Hansson
The effect of random error on the performance of blood-based biomarkers for Alzheimer's disease (AD) must be determined before clinical implementation.
-
APOE ε4 influences medial temporal atrophy and tau deposition in atypical Alzheimer's disease Alzheimers Dement. (IF 16.655) Pub Date : 2022-06-12 Neha Atulkumar Singh, Nirubol Tosakulwong, Jonathan Graff-Radford, Mary M. Machulda, Nha Trang Thu Pham, Irene Sintini, Stephen D. Weigand, Christopher G. Schwarz, Matthew L. Senjem, Minerva M. Carrasquillo, Nilufer Ertekin-Taner, Clifford R. Jack, Val J. Lowe, Keith A. Josephs, Jennifer L. Whitwell
Apolipoprotein E (APOE) ε4 is an important genetic risk factor for typical Alzheimer's disease (AD), influencing brain volume and tau burden. Little is known about its influence in atypical presentations of AD.
-
In Alzheimer's disease, amyloid beta accumulation is a protective mechanism that ultimately fails Alzheimers Dement. (IF 16.655) Pub Date : 2022-06-08 Elise Brøchner Rischel, Michael Gejl, Birgitte Brock, Jørgen Rungby, Albert Gjedde
Here, we claim that amyloid beta (Aβ) accumulation is a protective mechanism that ultimately fails. We predict that more Aβ accumulates in regions with higher rates of glucose metabolism, reaching a maximum followed by progression of pathology.
-
Association of neighborhood socioeconomic disadvantage and cognitive impairment Alzheimers Dement. (IF 16.655) Pub Date : 2022-06-06 Maria Vassilaki, Jeremiah A. Aakre, Anna Castillo, Alanna M. Chamberlain, Patrick M. Wilson, Walter K. Kremers, Michelle M. Mielke, Yonas E. Geda, Mary M. Machulda, Rabe E. Alhurani, Jonathan Graff-Radford, Prashanthi Vemuri, Val J. Lowe, Clifford R. Jack, David S. Knopman, Ronald C. Petersen
We investigated the association of the area deprivation index (ADI) with cognitive decline, mild cognitive impairment (MCI), and dementia in older adults (≥50 years old). ADI is a neighborhood socioeconomic disadvantage measure assessed at the census block group level.
-
A combination model of AD biomarkers revealed by machine learning precisely predicts Alzheimer's dementia: China Aging and Neurodegenerative Initiative (CANDI) study Alzheimers Dement. (IF 16.655) Pub Date : 2022-06-06 Feng Gao, Xinyi Lv, Linbin Dai, Qiong Wang, Peng Wang, Zhaozhao Cheng, Qiang Xie, Ming Ni, Yan Wu, Xianliang Chai, Wenjing Wang, Huaiyu Li, Feng Yu, Yuqin Cao, Fang Tang, Bo Pan, Guoping Wang, Kexue Deng, Shicun Wang, Qiqiang Tang, Jiong Shi, Yong Shen
To test the utility of the “A/T/N” system in the Chinese population, we study core Alzheimer's disease (AD) biomarkers in a newly established Chinese cohort.
-
Apolipoprotein E (APOE) genotype, dementia, and memory performance among Caribbean Hispanic versus US populations Alzheimers Dement. (IF 16.655) Pub Date : 2022-06-04 Jorge J. Llibre-Guerra, Jing Li, Yuting Qian, Juan de Jesús Llibre-Rodriguez, Ivonne Z. Jiménez-Velázquez, Daisy Acosta, Aquiles Salas, Juan Carlos Llibre-Guerra, Adolfo Valvuerdi, Amal Harrati, Jordan Weiss, Mao-Mei Liu, William H. Dow
Apolipoprotein E (APOE) is considered the major susceptibility gene for developing Alzheimer's disease. However, the strength of this risk factor is not well established across diverse Hispanic populations.
-
Global estimates on the number of persons across the Alzheimer's disease continuum Alzheimers Dement. (IF 16.655) Pub Date : 2022-06-02 Anders Gustavsson, Nicholas Norton, Thomas Fast, Lutz Frölich, Jean Georges, Drew Holzapfel, Tunahan Kirabali, Pierre Krolak-Salmon, Paolo M. Rossini, Maria Teresa Ferretti, Lydia Lanman, Antonella Santuccione Chadha, Wiesje M. van der Flier
Global estimates on numbers of persons in early stages of Alzheimer's disease (AD), including prodromal and preclinical, are lacking, yet are needed to inform policy decisions on preventive measures and planning for future therapies targeting AD pathology.
-
Education, neighborhood environment, and cognitive decline: Findings from two prospective cohort studies of older adults in China Alzheimers Dement. (IF 16.655) Pub Date : 2022-05-31 Yingzhe Wang, Yanfeng Jiang, Wanqing Wu, Kelin Xu, Qianhua Zhao, Ziyi Tan, Xiaoniu Liang, Min Fan, Zhenxu Xiao, Li Zheng, Saineng Ding, Qiang Dong, Zhen Hong, Li Jin, Xingdong Chen, Ding Ding, Mei Cui
The impacts of education on cognitive decline across different neighborhood environments (NEs) have rarely been studied.
-
Subcortical brain structures and the risk of dementia in the Rotterdam Study Alzheimers Dement. (IF 16.655) Pub Date : 2022-05-28 Isabelle F. van der Velpen, Vanja Vlasov, Tavia E. Evans, Mohammad Kamran Ikram, Boris A. Gutman, Gennady V. Roshchupkin, Hieab H. Adams, Meike W. Vernooij, Mohammad Arfan Ikram
Volumetric and morphological changes in subcortical brain structures are present in persons with dementia, but it is unknown if these changes occur prior to diagnosis.
-
Patterns and implications of neurological examination findings in autosomal dominant Alzheimer disease Alzheimers Dement. (IF 16.655) Pub Date : 2022-05-24 Jonathan Vöglein, Nicolai Franzmeier, John C. Morris, Marianne Dieterich, Eric McDade, Mikael Simons, Oliver Preische, Anna Hofmann, Jason Hassenstab, Tammie L. Benzinger, Anne Fagan, James M. Noble, Sarah B. Berman, Neill R. Graff-Radford, Bernardino Ghetti, Martin R. Farlow, Jasmeer P. Chhatwal, Stephen Salloway, Chengjie Xiong, Celeste M Karch, Nigel Cairns, Richard J. Perrin, Gregory Day, Ralph
As knowledge about neurological examination findings in autosomal dominant Alzheimer disease (ADAD) is incomplete, we aimed to determine the frequency and significance of neurological examination findings in ADAD.
-
ISTAART Professional Interest Area to Elevate Early Career Researchers and University College London survey turns a spotlight on early career researcher life and challenges. Alzheimers Dement. (IF 16.655) Pub Date : 2022-05-25 Adam Smith,C Elizabeth Shaaban,Sara Laureen Bartels,Wagner S Brum,Lindsay A Welikovitch,Royhaan O Folarin
-
Mendelian randomization highlights causal association between genetically increased C-reactive protein levels and reduced Alzheimer's disease risk. Alzheimers Dement. (IF 16.655) Pub Date : 2022-05-22 Yang Hu,Yan Zhang,Haihua Zhang,Shan Gao,Longcai Wang,Tao Wang,Zhifa Han,,Guiyou Liu
-
Reply to "Mendelian randomization highlights causal association between genetically increased C-reactive protein levels and reduced Alzheimer's disease risk". Alzheimers Dement. (IF 16.655) Pub Date : 2022-05-22 Jiao Luo,Jesper Qvist Thomassen,Sharif H Hegazy,Ida Juul Rasmussen,Børge G Nordestgaard,Anne Tybjaerg-Hansen,Ruth Frikke-Schmidt
-
Response to “Upping the dose of dementia risk reduction” Alzheimers Dement. (IF 16.655) Pub Date : 2022-05-16 Sylvie Belleville, Simon Cloutier, Samira Mellah, Bruno Vellas, Sandrine Andrieu, Nicola Coley, Tiia Ngandu
Timothy Daly commented on our article reporting a dose effect in a multidomain intervention to prevent cognitive decline in older adults at risk of dementia.1 Our article modeled the dose-response relationship in a multidomain intervention and identified an optimal dosage and dose differences based on individual characteristics, such as level of frailty and education. Although Daly recognizes that
-
Upping the dose of dementia risk reduction. Alzheimers Dement. (IF 16.655) Pub Date : 2022-05-08 Timothy Daly
-
Higher Dietary Inflammatory Index scores are associated with brain MRI markers of brain aging: Results from the Framingham Heart Study Offspring cohort Alzheimers Dement. (IF 16.655) Pub Date : 2022-05-06 Deborah Melo Van Lent, Hannah Gokingco, Meghan I. Short, Changzheng Yuan, Paul F. Jacques, José R. Romero, Charles S. DeCarli, Alexa S. Beiser, Sudha Seshadri, Jayandra J. Himali, Mini E. Jacob
We investigated cross-sectional associations between the Dietary Inflammatory Index (DII) and measures of brain volume and cerebral small vessel disease among participants of the Framingham Heart Study Offspring cohort.
-
The role of mitochondrial dysfunction in Alzheimer's disease pathogenesis Alzheimers Dement. (IF 16.655) Pub Date : 2022-05-06 Theophania Ashleigh, Russell H. Swerdlow, M. Flint Beal
To promote new thinking of the pathogenesis of Alzheimer's disease (AD), we examine the central role of mitochondrial dysfunction in AD. Pathologically, AD is characterized by progressive neuronal loss and biochemical abnormalities including mitochondrial dysfunction. Conventional thinking has dictated that AD is driven by amyloid beta pathology, per the Amyloid Cascade Hypothesis. However, the underlying
-
Genetic variants in the SHISA6 gene are associated with delayed cognitive impairment in two family datasets Alzheimers Dement. (IF 16.655) Pub Date : 2022-05-01 Jairo Ramos, Laura J. Caywood, Michael B. Prough, Jason E. Clouse, Sharlene D. Herington, Susan H. Slifer, M. Denise Fuzzell, Sarada L. Fuzzell, Sherri D. Hochstetler, Kristy L. Miskimen, Leighanne R. Main, Michael D. Osterman, Andrew F. Zaman, Patrice L. Whitehead, Larry D. Adams, Renee A. Laux, Yeunjoo E. Song, Tatiana M. Foroud, Richard P. Mayeux, St. George-Hyslop Peter, Paula K. Ogrocki, Alan
Studies of cognitive impairment (CI) in Amish communities have identified sibships containing CI and cognitively unimpaired (CU) individuals. We hypothesize that CU individuals may carry protective alleles delaying age at onset (AAO) of CI.
-
Longitudinal changes in cerebral blood flow and their relation with cognitive decline in patients with dementia: Current knowledge and future directions Alzheimers Dement. (IF 16.655) Pub Date : 2022-04-29 Ralf W.J. Weijs, Daria A. Shkredova, Anna C.M. Brekelmans, Dick H.J. Thijssen, Jurgen A.H.R. Claassen
The pathophysiology underlying cognitive decline is multifactorial, with increasing literature suggesting a role for cerebrovascular health. Cerebral blood flow (CBF) is an important element of cerebrovascular health, which raises questions regarding the relation between CBF and cognitive decline. Cross-sectional studies demonstrate lower CBF in patients with cognitive decline compared to healthy age-matched
-
Predictive metabolic networks reveal sex- and APOE genotype-specific metabolic signatures and drivers for precision medicine in Alzheimer's disease Alzheimers Dement. (IF 16.655) Pub Date : 2022-04-28 Rui Chang, Eugenia Trushina, Kuixi Zhu, Syed Shujaat Ali Zaidi, Branden M. Lau, Alexandra Kueider-Paisley, Sara Moein, Qianying He, Melissa L. Alamprese, Barbora Vagnerova, Andrew Tang, Ramachandran Vijayan, Yanyun Liu, Andrew J. Saykin, Roberta D. Brinton, Rima Kaddurah-Daouk
Late-onset Alzheimer's disease (LOAD) is a complex neurodegenerative disease characterized by multiple progressive stages, glucose metabolic dysregulation, Alzheimer's disease (AD) pathology, and inexorable cognitive decline. Discovery of metabolic profiles unique to sex, apolipoprotein E (APOE) genotype, and stage of disease progression could provide critical insights for personalized LOAD medicine
-
Modifying effects of race and ethnicity and APOE on the association of physical activity with risk of Alzheimer's disease and related dementias Alzheimers Dement. (IF 16.655) Pub Date : 2022-04-27 Song-Yi Park, Veronica Wendy Setiawan, Lon R. White, Anna H. Wu, Iona Cheng, Christopher A. Haiman, Lynne R. Wilkens, Loїc Le Marchand, Unhee Lim
We investigated whether the protective association of physical activity with risk of Alzheimer's disease and related dementias (ADRD) has genetic or behavioral variations.